The largest database of trusted experimental protocols
> Chemicals & Drugs > Pharmacologic Substance > Cholinergic Agents

Cholinergic Agents

Cholinergic Agents are a class of pharmacologically active substances that interact with cholinergic receptors, which are involved in a variety of physiological processes.
These agents can have stimulatory or inhibitory effects on the cholinergic system, making them important therapeutic targets for conditions affecting the nervous system, cardiovascular system, and other bodily functions.
Researchers can leverage the power of PubCompare.ai to optimzie their research protocols for Cholinergic Agents, exploring a wealth of literature, pre-prints, and patents to identify the best protocols and products for their needs.
This AI-driven platform streamlines the research workflow, helping scientists take their Cholinergic Agents research to new heights.

Most cited protocols related to «Cholinergic Agents»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2008
1,2-dihexadecyl-sn-glycero-3-phosphocholine Alabaster austin Brain Stem Buffers Cells Cerebellum Chloroform Cholinergic Agents Cold Temperature Cycloheximide Deoxyribonucleases Digestion Dithiothreitol Endoribonucleases Ethanol G-substrate Goat HEPES inhibitors Isopropyl Alcohol Lipids Magnesium Chloride Mice, Laboratory Mice, Transgenic Motor Neurons Nonidet P-40 Polyribosomes Protease Inhibitors Purkinje Cells Ribosomal RNA RNA, Messenger Sodium Acetate Sodium Chloride Striatum, Corpus Teflon Tissues trizol
Cellular [Ca2+]i and electrophysiological methods are described in the Online Supplement and were used to tune our model and for validation. Table 1 shows key changes made in our new human atrial model vs. our ventricular myocyte model, 12 (link) to account for ionic remodeling in cAF, and to simulate the effects of β-adrenergic and cholinergic stimulation. Further details are in Online Supplement, including formulation of IKur block by AVE0118.
Model differential equations were implemented in Matlab (Mathworks Inc., Natick, MA, USA) and solved numerically using a variable order solver (ode15s). APDs were obtained after pacing digital cells at indicated frequencies at steady-state. APD was measured as the interval between AP upstroke and 90% repolarization level (APD90).
Publication 2011
Adrenergic Effect AVE 0118 Cells Cholinergic Agents Dietary Supplements Electric Stimulation Therapy Heart Atrium Heart Ventricle Homo sapiens Ions Muscle Cells

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2019
Biological Processes Cholinergic Agents gamma Aminobutyric Acid Hydrochloride, Dopamine Neuromuscular Junction Parent Strains Synapses Trees Vision
All experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources 1996 ) as adopted and promulgated by the National Institutes of Health. Timed-pregnant Sprague-Dawley rats (Charles River, Raleigh, NC) were housed in breeding cages, with a 12-hr light/dark cycle and free access to food and water. On the day of birth, all pups were randomized and redistributed to the dams with a litter size of 9–10 to maintain a standard nutritional status; for treatment groups with high pup mortality rates (not used for neuro-chemical analyses), litter sizes were maintained in this range by combining groups of survivors. Chlorpyrifos, diazinon, and parathion (all from Chem Service, West Chester, PA) were dissolved in DMSO to provide consistent absorption (Whitney et al. 1995 (link)) and were injected subcutaneously in a volume of 1 mL/kg once daily on postnatal days (PND) 1–4; control animals received equivalent injections of the DMSO vehicle. For chlorpyrifos, we used daily doses of 1 mg/kg and 5 mg/kg, straddling the threshold for growth retardation and systemic toxicity (Campbell et al. 1997 (link); Whitney et al. 1995 (link)). The lower dose produces neurotoxicity in developing rat brain with only 20% cholinesterase inhibition (Slotkin 1999 (link), 2004 (link); Song et al. 1997 (link); Whitney et al. 1995 (link)), well below the 70% threshold necessary for symptoms of cholinergic hyperstimulation (Clegg and van Gemert 1999 ). This treatment thus resembles the nonsymptomatic exposures reported in pregnant women (De Peyster et al. 1993 (link)) and is within the range of expected fetal and childhood exposures after routine home application or in agricultural communities (Gurunathan et al. 1998 (link); Ostrea et al. 2002 (link)). For diazinon and parathion, prior information on systemic toxicity using this vehicle and route was not available, so we evaluated a wider range of doses: 0.05–5 mg/kg for diazinon and 0.01–5 mg/kg for parathion. As shown in “Results,” just as for chlorpyrifos, the diazinon and parathion doses ranged from those with no discernible effect on growth or viability to those lying above the threshold for overt toxicity.
On PND5, one male and one female pup were selected from each of six litters in each treatment group and were used for neuro-chemical evaluations. Animals were decapitated, the cerebellum was removed, and the brainstem and forebrain were separated by a cut made rostral to the thalamus. Tissues were weighed, flash-frozen in liquid nitrogen, and maintained at −45°C until analysis.
Full text: Click here
Publication 2006
Animals Animals, Laboratory Birth Brain Brain Stem Care, Prenatal Cerebellum Chlorpyrifos Cholinergic Agents Cholinesterases Diazinon Females Food Freezing Males Neurotoxicity Syndromes Nitrogen Ostrea Parathion Patient Holding Stretchers Pregnant Women Prosencephalon Psychological Inhibition Rats, Sprague-Dawley Rivers Sulfoxide, Dimethyl Survivors Thalamus Tissues
After normalization of intensities between images, terminals and dendrites were segmented based on morphology and Syt::smGFP-HA distribution using FluoRender (Wan et al., 2009 (link), 2012 (link)). To determine the distribution of projections in different brain regions shown in Figure 18E, signals from the cell types making up each of five groups—glutamatergic, GABAergic and cholinergic MBONs and the PPL1 and PAM DANs—were averaged within a group. Then the total signal within the volume of each neuropil mask for each of the five groups was divided by total signal observed in all neuropils. To calculate signal intensities shown in Figure 19C, the average of signals in 10 × 10 × 10 voxel volumes (3.8 µm in each dimension) were used.
To estimate degree of overlap between processes of MBONs and DANs in Figure 20, we used the method previously described by Cachero et al. (2010) (link). We had multiple images for each cell type and we treated the two brain hemispheres separately, giving us on average 17.4 image pairs per cell type combination. We computed the overlap for each image pair separately; each cell in the matrices shown in Figure 20A–C represents the mean value.
Full text: Click here
Publication 2014
Brain Cells Cerebral Hemispheres Cholinergic Agents Cytosol Dendrites Neuropil

Most recents protocols related to «Cholinergic Agents»

For analysis of cholinergic markers, rats were deeply anesthetized (5% isoflurane) followed by intracardiac perfusion with clearing solution (0.1 M phosphate buffer, 0.5 mM EDTA, 0.05% NaNO2) followed by ice cold 0.1 M phosphate buffer (PB, pH 7.4) containing 4% paraformaldehyde. Brains were removed and placed in 4% paraformaldehyde (0.1 M PB, pH 7.4) to postfix at 4°C. Coronal sections containing the basal forebrain and the amygdala plus hippocampus were cut at 50 μm on a vibratome (VT1000S, Leica, Nussloch, Germany) and stored at 4°C in 0.1 M phosphate buffer until staining. For longer term storage, sections were transferred to Anti‐freezing solution (30% Sucrose in 0.1 M phosphate buffer with 30% ethylene glycol), then stored at −20°C.
Immunofluorescence labeling for ChAT and VAChT used methods described in Tryon et al., (2022).47 For ChAT immunolabeling, sections were washed three times in Tris buffer (TBS) for 10 min, blocked in TBS containing 0.5% Triton X‐100 and 10% normal donkey serum for 30 min at room temperature, washed in TBS then incubated with goat polyclonal anti‐choline acetyltransferase antibodies (1:1000; Millipore Cat# AB144P, RRID:AB_2079751;used previously in47) in TBS containing 0.5% Triton X‐100 and 2% normal donkey serum for 2 days at room temperature. Sections were then incubated in donkey‐anti goat conjugated to Alexa Fluor 647 (1:400; Jackson ImmunoResearch Labs Cat# 705‐605‐147, RRID:AB_2340437) in TBS with 0.5% Triton X‐100 and 2% normal donkey serum for 3 h at room temperature. To detect labeling of vesicular acetylcholine transporter (VAChT), separate sections were washed three times in TBS then blocked for 30 min at room temperature in TBS containing 0.5% Triton X‐100 and 10% normal donkey serum, after which they were washed three times in TBS. Sections were incubated in TBS containing goat anti‐vesicular acetylcholine transporter antibodies (1:1000; Millipore Cat# ABN100, RRID:AB_2630394), 0.5% Triton X‐100 and 2% normal donkey serum overnight at room temperature. Sections were washed three times in TBS then incubated in TBS containing donkey‐anti goat conjugated to Alexa Fluor 555 (1:500; Molecular Probes Cat# A‐21432, RRID:AB_141788), 0.5% Triton X‐100 and 2% normal donkey serum. Sections labeled for ChAT were coverslipped in Vectashield Vibrance Antifade Mounting Media (Vector Laboratories Cat#H‐1700, Burlingame, CA) and sections labeled for VAChT were coverslipped in Prolong Gold Antifade Mountant (Thermo Fisher Scientific, Waltham, MA) and stored at 4°C until imaging.
Coronal sections including the BF, BLA and hippocampus were also stained for acetylcholinesterase (ACHE) activity. As described previously, sections were incubated in a solution of 0.2 M Tris maleate buffer (pH 5.7), 0.1 M sodium citrate, 0.03 M cupric sulfate, 5 mM potassium ferricyanide, and 1.7 mM acetylthiocholine iodide for ~60 min at room temperature followed by a 70% ethanol rinse and coverslipping.48, 49
Publication 2023
Acetylcholinesterase Acetylcholine Transporters, Vesicular acetylthiocholine iodide Alexa Fluor 555 Alexa Fluor 647 Amygdaloid Body Anti-Antibodies Basal Forebrain Brain Buffers Choline O-Acetyltransferase Cholinergic Agents Cloning Vectors Cold Temperature Edetic Acid Equus asinus Ethanol Fluorescent Antibody Technique Glycol, Ethylene Goat Gold Isoflurane maleate Molecular Probes paraform Perfusion Phosphates potassium ferricyanide Rattus Seahorses Serum Sodium Citrate Sucrose Sulfate, Copper Triton X-100 Tromethamine
All animal treatments and procedures were in compliance with the American Association for Laboratory Animal Science (AALAS) and experimental procedures were approved by both the University of South Carolina and Columbia VA Health Care System Institutional Care and Use Committees. Upon arrival, rats were maintained in the vivarium on a 12‐hour light/dark cycle with ad libitum access to food and water. As Long Evans Tg (ChAT::Cre) rats originally developed by the Deisseroth group have genetically‐restricted expression of Cre recombinase in cholinergic (ChAT expressing) neurons,26 four ChAT:Cre hemizygous male rats were purchased from the Rat Resource and Research Center (RRRC# 00658: Long Evans‐Tg(ChAT‐Cre)5.1Deis; University of Missouri, Columbia MO; RRID:RRRC_00658) and were ~ 2 months of age upon arrival. They were bred with four adult female wildtype Long Evans rats (~2 months old on arrival; Envigo RRID:RGD_5508398). The day before weaning, rat pups were color coded by tail marking and each given a unique number. At 21 days, the four resulting litters (N = 41 pups) were weaned. At weaning, tail snips were taken (~1 mm) with a sterile scalpel and placed into a labeled 96 well plate (provided by TransnetYX). The plate was sealed and sent to TransnetYX (Cordova, TN) for genotyping using polymerase chain reaction (PCR) for detection of the Cre recombinase gene.
Following weaning, animals were housed in groups of 2–3 with same‐sex littermates, but were single housed starting ~2 weeks prior to behavioral testing per our previous studies.17, 42, 43 Breeding of the transgenic ChAT::Cre+ males with wildtype females yielded 41 offspring that were tested in a cue‐conditioned fear and extinction protocol during early light phase of the light: dark cycle (see Figure 1; as described in17, 42, 43). The groups tested were Cre+ males (N = 12), Cre‐ males (N = 8), Cre+ females (N = 15), and Cre‐ females (N = 6). Unfortunately, due to the COVID‐19 pandemic we were unable to add additional litters to create similar sample sizes in each group.
Males and females were handled for 2 weeks prior to behavioral testing, and daily vaginal lavage was performed in the females to determine estrous cycle stage; males were handled similarly. Vaginal lavage was also performed after behavioral testing each day to assess the stage of the cycle during each behavioral test while avoiding additional handling stress.43, 44, 45 Vaginal cytology was determined using the fresh cytology samples under a microscope, and slides were then fixed using 95% ethanol for additional staining using hematoxylin and eosin for additional verification (see Refs. 43 (link), 44 (link) for detailed methods).
Publication 2023
Animals Animals, Transgenic Behavior Test Cholinergic Agents COVID 19 Cre recombinase Cytological Techniques Eosin Estrous Cycle Ethanol Extinction, Psychological Fear Females Food Genes Hematoxylin Hemizygote Light Males Microscopy Neurons Patient Holding Stretchers Polymerase Chain Reaction Rats, Long-Evans Sterility, Reproductive Tail Vagina Vaginal Douching Woman
All animal procedures were approved by the UC Berkeley Institutional Animal Care and Use Committee and conformed to the NIH Guide for the Care and Use of Laboratory Animals (AUP-2015-10-8080-2), the Public Health Service Policy, and the SFN Policy on the Use of Animals in Neuroscience Research. For our calcium dye-based calcium imaging, Opn4Cre/+;Ai9 mice were generated by crossing mice Opn4Cre/+ B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato) Hze/J mice (Ai9) mice (stock # 007909, Jackson Laboratory, Bar Harbor, ME) to the Opn4Cre/+ reporter mouse (T. Schmidt, Northwestern University, Evanston, IL). For our GCaMP6s-based calcium imaging, we generated Vglut2;GCaMP6s mice by crossing B6J.129S6(FVB)-Slc17a6tm2(cre)Lowl/MwarJ mice (stock # 028866) to B6J.Cg-Gt (ROSA)26Sortm96(CAG-GCaMP6s)Hze/MwarJ mice (stock # 028863). ipRGC density measurements were conducted on P1–P7 mice of either sex using Opn4Cre/+;Ai9.
To obtain mice that were precisely at the correct embryonic age, we set up timed pregnancies and checked vaginal plugs every morning for 4 days after the animals were paired. This approach led to an uncertainty of age of ± 1 day. Hence, we grouped data across E16–18. Since we observed more variance within litters than across litters, we assume age was not a determining factor in our findings. We used the β2-nAChR-KO mouse line in which the β subunit of the nicotinic acetylcholine receptor is knocked out as a genetic model in which cholinergic retinal spontaneous activity is disrupted. For experiments regarding the influence of spontaneous retinal activity on the distribution of ipRGCs across the retina, we used β2-/-::Opn4Cre/+;Ai9 (β2-nAChR-KO) mice, generated by crossing β2-/- (A. Beaudet, Baylor University, Waco, TX) mice to Opn4Cre/+;Ai9 mice to label all melanopsin-expressing cells. All mouse lines are maintained on a C57BL/6 genetic background. All animals used for two-photon calcium imaging experiments and immunohistochemistry were housed in 12 hr day/night cycle rooms.
Full text: Click here
Publication 2023
A-factor (Streptomyces) Animals Animals, Laboratory Calcium Cells Cholinergic Agents Embryo factor A Genetic Background Immunohistochemistry Institutional Animal Care and Use Committees melanopsin Mice, Laboratory Nicotinic Receptors Patient Holding Stretchers Pregnancy Protein Subunits Retina Rosa tdTomato Vagina
Apatinib was given as a fixed dose of 250 mg once a day, within 30 min after breakfast. Sintilimab was given within 60 min before chemotherapy by intravenous infusion of a fixed dose of 200 mg every 3 weeks. Antiemetic drugs were given by intravenous infusion 30 min before chemotherapy with either irinotecan (150 mg/m2, 90-minute intravenous infusion once every 2 weeks) or paclitaxel (150 mg/m2, 3-hour intravenous infusion once every 3 weeks). Considering that compared with monotherapy combination may increase the risk of toxic reactions, and chemotherapy is more important to play an immunomodulatory role in the combination therapy, the dose of chemotherapy drugs in this study was lowered compared with the conventional dose. Prophylactic atropine was given before the next irinotecan infusion treatment for patients with acute cholinergic syndrome. To prevent allergic reaction, 10 mg of oral dexamethasone was given 12 and 6 h before paclitaxel administration, and 400 mg of intravenous cimetidine and 50 mg of intramuscular diphenhydramine were given 30 min before paclitaxel administration. An intravenous infusion of sintilimab every 3 weeks is considered one cycle. Apatinib and sintilimab were continued until the disease progressed or became intolerable or up to 2 years, and the chemotherapy drug irinotecan or paclitaxel was continued until the disease progression, intolerable toxicity, or up to 6 months. If adverse events occurred during treatment, symptomatic and supportive treatments were given according to clinical protocol. Immune-related adverse events were treated with reference to the NCCN immune-related toxicity management guidelines. Blood or urine laboratory tests such as routine blood parameters, blood biochemistry, heart function, routine urinalysis, and thyroid function were regularly performed according to clinical protocol. Contrast-enhanced computed tomography of chest, abdomen, and pelvis was carried out every 6 weeks until progressive disease (PD) was confirmed. Response was determined by the investigators according to RECIST 1.1. Adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Patients with PD after the study treatment were followed up every 3 months by telephone until death.
Full text: Click here
Publication 2023
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Abdomen Allergic Reaction Antiemetics apatinib Atropine BLOOD Chest Cholinergic Agents Cimetidine Clinical Protocols Combined Modality Therapy Condoms Dexamethasone Diphenhydramine Disease Progression Heart Hematologic Tests Immunomodulation Intravenous Infusion Irinotecan Paclitaxel Patients Pelvis Pharmaceutical Preparations Pharmacotherapy sintilimab Syndrome Thyroid Gland Urinalysis Urine X-Ray Computed Tomography
A comprehensive set of receptor–ligand binding studies were conducted with prucalopride and its metabolites at a wide range of concentrations, from 0.1 nM to 1 mM. The effect of prucalopride on the uptake of monoamine neurotransmitters, peptide receptors, ion channel binding sites, monoamine neurotransmitter transporters and γ-aminobutyric acid was investigated. In addition, the functional effects of prucalopride (up to 100 μM) on intracellular concentrations of Ca2+ in intact mammalian cells expressing human [h] 5-HT2A, 5-HT2B, 5-HT2C, 5-HT4A and 5-HT4B receptors were assessed. The following receptors, ion channels or transporters were included: neurotransmitter receptor binding sites (serotonergic, adrenergic, dopaminergic, histamine and r-cholinergic muscarinic); drug receptor binding sites; ion channel ligand binding sites; peptide receptor binding sites (neurokinin, bradykinin, cholecystokinin and h-vasoactive intestinal peptide); lipid-derived factor binding sites; monoamine transporter sites; and [3H] γ-aminobutyric acid (GABA) uptake in crude rat synaptosome preparations. Additional methodological details are provided in Tables S1 and S2.
Publication 2023
5-hydroxytryptamine receptor 2C, human Adrenergic Agents Binding Sites Bradykinin Cells Cholecystokinin Cholinergic Agents gamma Aminobutyric Acid Histamine Homo sapiens Hydrochloride, Dopamine Ion Channel Ligands Lipids Mammals Membrane Transport Proteins Muscarinic Agents Neurokinin A Neurotransmitter Receptor Neurotransmitters Neurotransmitter Transport Proteins Peptide Receptor Protoplasm prucalopride Receptors, Drug Synaptosomes Vasoactive Intestinal Peptide

Top products related to «Cholinergic Agents»

Sourced in United States, Germany
The AB144P is a laboratory equipment product from Merck Group. It is a multi-purpose device designed for various laboratory applications. The core function of the AB144P is to perform precise measurements and analyses in a controlled environment. Further details on the specific intended use of this product are not available.
Sourced in United States
BFGF) recombinant human protein is a laboratory reagent produced by Thermo Fisher Scientific. It is a purified, recombinant form of the basic fibroblast growth factor (bFGF) protein. bFGF is a signaling molecule involved in various cellular processes. The core function of this product is to provide a source of bFGF for use in research applications.
Sourced in United States, Germany, France, Italy, United Kingdom
Kynurenic acid is a chemical compound that is commonly used in laboratory research. It is a metabolite of the amino acid tryptophan and is known to have various biological functions. The core function of kynurenic acid is to serve as a biochemical tool for scientific investigation and analysis, particularly in the fields of neuroscience and immunology.
Sourced in United States, Germany, Sao Tome and Principe, United Kingdom, France
Pilocarpine is a pharmaceutical compound commonly used in laboratory settings. It functions as a cholinergic agonist, primarily activating muscarinic acetylcholine receptors. This product is utilized in various research applications, including the study of autonomic nervous system responses and the evaluation of ocular effects.
Sourced in United States
The Grass S48 stimulator is a laboratory device designed to generate electrical stimuli. It provides precise control over the timing, intensity, and frequency of electrical pulses for use in various experimental and research applications. The core function of the Grass S48 stimulator is to deliver controlled electrical stimulation to samples or subjects under investigation.
Sourced in Germany, United States, United Kingdom, Netherlands, Spain, Japan, Canada, France, China, Australia, Italy, Switzerland, Sweden, Belgium, Denmark, India, Jamaica, Singapore, Poland, Lithuania, Brazil, New Zealand, Austria, Hong Kong, Portugal, Romania, Cameroon, Norway
The RNeasy Mini Kit is a laboratory equipment designed for the purification of total RNA from a variety of sample types, including animal cells, tissues, and other biological materials. The kit utilizes a silica-based membrane technology to selectively bind and isolate RNA molecules, allowing for efficient extraction and recovery of high-quality RNA.
Sourced in United States, United Kingdom, Sao Tome and Principe, Canada
Atropine sulfate is a chemical compound commonly used in laboratory settings. It acts as a muscarinic antagonist, blocking the action of the neurotransmitter acetylcholine on muscarinic receptors. The core function of atropine sulfate is to inhibit the parasympathetic nervous system, leading to physiological effects such as pupil dilation, reduced salivation, and altered heart rate.
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, Macao
Pilocarpine hydrochloride is a chemical compound that is commonly used in laboratory settings. It is a crystalline solid with the molecular formula C11H16N2O2·HCl. Pilocarpine hydrochloride is a cholinergic agent, which means it acts on the parasympathetic nervous system to produce various physiological effects.
Sourced in United States, Germany, United Kingdom, Italy, Sao Tome and Principe, Spain, France, China, Switzerland, Macao
Acetylcholine is a chemical compound that functions as a neurotransmitter in the body. It plays a crucial role in the transmission of signals between nerve cells and muscle cells, as well as within the central nervous system.
Sourced in United Kingdom, France, United States
Dihydro-β-erythroidine hydrobromide (DHβE) is a pharmacological compound used in research applications. It functions as a nicotinic acetylcholine receptor antagonist. The core purpose of this product is to facilitate studies and experiments involving the modulation of nicotinic acetylcholine receptor activity.

More about "Cholinergic Agents"

Cholinergic agents, also known as acetylcholine agonists, are a class of pharmacologically active substances that interact with cholinergic receptors, which are involved in a variety of physiological processes.
These agents can have stimulatory or inhibitory effects on the cholinergic system, making them important therapeutic targets for conditions affecting the nervous system, cardiovascular system, and other bodily functions.
Researchers can leverage the power of PubCompare.ai, an AI-driven platform, to optimize their research protocols for Cholinergic Agents.
This platform allows scientists to explore a wealth of literature, pre-prints, and patents, and use intelligent comparisons to identify the best protocols and products for their research needs.
Streamlining the research workflow, PubCompare.ai helps researchers take their Cholinergic Agents research to new heights.
Key subtopics related to Cholinergic Agents include Acetylcholine (ACh), the primary neurotransmitter in the cholinergic system, and its agonists and antagonists, such as Pilocarpine, Atropine sulfate, and Dihydro-β-erythroidine hydrobromide (DHβE).
Researchers may also utilize related compounds like AB144P, a recombinant human protein, BFGF, and Kynurenic acid, to study the effects of Cholinergic Agents on various physiological processes.
Additionally, techniques such as the RNeasy Mini Kit, a RNA extraction kit, can be employed to analyze the expression of cholinergic receptors and related genes.
The Grass S48 stimulator, a device used to study nerve and muscle function, may also be utilized in Cholinergic Agents research.
By leveraging the insights and tools provided by PubCompare.ai, researchers can optimize their investigations into Cholinergic Agents, leading to advancements in the understanding and treatment of conditions related to the cholinergic system.